Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure

ConditionLiver Failure
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorKebo Zhong

About this trial

The goal of this clinical trial is to learn if mesenchymal stem cells in blood purification works to treat liver failure in adults. It will also learn about the safety and effectiveness of mesenchymal stem cells in blood purification. The main questions it aims to answer are:1.Does mesenchymal stem cells in blood purification improve the condition of patients with liver failure? 2.What medical problems do participants have when taking mesenchymal stem cells in blood purification? Participants will receive routine medical treatment and blood purification treatment with mesenchymal stem cells.These cells work outside the body and do not enter the body. We will: 1.Collect samples from participants such as blood, Urine and feces. 2.record post-treatment outcomes such as survival rate at 4 weeks after treatment, conversion rate to liver transplantation, Inflammatory, survival rate at 7days, 14days, 8 weeks and 12 weeks after treatment, and liver disease indicators(prothrombin time activity percentage, lactic aicd, blood ammonia, α-fetoprotein, ferritin).

Eligibility criteria

Qualifiers

Age range from 18 to 65 years old;

Patients with acute liver failure in the early and intermediate stages caused by various reasons;

Total bilirubin (TBil) ≥ 171μmol/L or an increase of ≥ 17.1μmol/L per day;

Prothrombin activity (PTA) between 20% and 40% (or INR between 1.5 and 2.6);

Disqualifiers

Patients with severe active bleeding or diffuse intravascular coagulation;

Patients with a high degree of allergy to blood products or drugs used during treatment, such as plasma, heparin, and protamine;

Patients with circulatory failure;

Patients with a MELD score > 30;

Trial design

Treatments tested in this trial

  • It is loaded with a mesenchymal stem cells reaction device for blood purification

Treatment groups

10 Participants
are divided into 1 treatment group

Sponsors and collaborators

Kebo Zhong

Lead sponsor

Zhujiang Hospital

Sponsor institution